1.	Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients Phase: Phase III, Phase II Type: Treatment Status: Closed Age: Over 18 Sponsor: Other Protocol IDs: GEICAM/2006-14, Nº EudraCT 2007-007031-13, NCT00841828
2.	Phase III Randomized Study of Paclitaxel With or Without GW572016 as First-Line Therapy in Women With Advanced or Metastatic Breast Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GSK-EGF30001, NCT00075270
3.	Phase III Randomized Study of Capecitabine With Versus Without Lapatinib in Women With Refractory Locally Advanced or Metastatic Breast Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GSK-EGF100151, UCLA-0403074-01, NCT00078572
4.	ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EGF104383, NCT00272987
5.	Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2 Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EGF104535, NCT00281658
6.	Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EGF104900, NCT00320385
7.	Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00475, 40302, U10CA031946, CDR0000510452, CALGB-40302, NCT00390455
8.	Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EGF105485, NCT00374322
9.	Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery Phase: Phase III Type: Treatment Status: Closed Age: 18 to 70 Sponsor: Pharmaceutical / Industry Protocol IDs: EGF102988, NCT00424255
10.	A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: NSABP B-41, NCT00486668
11.	Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Cancer Phase: Phase III Type: Treatment Status: Closed Age: 20 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 104578, NCT00486954
12.	ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: EGF106708, NCCTG-N063D, N063D, BIG 2-06, MAC.13, NCT00490139
13.	Lapatinib +Capecitabine Treatment for Advanced Metastatic Breast Cancer in Women From China Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EGF109491, NCT00508274
14.	Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EGF106903, NCT00553358
15.	A Phase III Trials Program Exploring the Integration of Bevacizumab, Everolimus (RAD001), and Lapatinib Into Current Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer Phase: Phase III Type: Genetics, Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: GBG 44, EudraCT No.: 2006-005834-19, NCT00567554
16.	Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: MA31, CAN-NCIC-MA31, GSK-EGF108919, EUDRACT-2007-004568-27, CDR0000594764, NCT00667251
17.	LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EGF110656, NCT00680901
18.	Phase III Randomized Study of Neoadjuvant Paclitaxel in Combination With Trastuzumab (Herceptin®) With or Without Lapatinib Ditosylate in Patients With HER2-Positive Resectable Stage II or III Breast Cancer Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: CALGB-40601, CALGB 40601, NCT00770809
19.	Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 111438, NCT00820222
20.	Lapatinib/Carboplatin/Paclitaxel in Previously Treated Ovarian or Breast Cancer Patients Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: CRC 0503, NCT00316407
21.	INST 0514C- Biologic Correlative Study: Trial of GW572016 in HER2 Overexpressing Breast Cancer Patients Phase: Phase II, Phase I Type: Treatment Status: Completed Age: Over 18 Sponsor: Other Protocol IDs: INST 0514C, NCT00455039
22.	Combination Chemotherapy and Radiation Therapy With or Without Lapatinib in Treating Patients With Locally Advanced Cancer of the Larynx or Hypopharynx Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: Over 18 Sponsor: Other Protocol IDs: CDR0000553410, EORTC-24051, EUDRACT-2006-002667-33, GSK-EORTC-24051, NCT00498953
23.	Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: 3144A1-2206, B1891017, NCT00741260
24.	Lapatinib in Treating Patients With Recurrent Glioblastoma Multiforme Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: I170, CAN-NCIC-IND170, CDR0000389155, NCIC-170, IND170, NCT00099060
25.	Study to Assess dHER2+AS15 Cancer Vaccine Given in Combination With Lapatinib to Patients With Metastatic Breast Cancer Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: Pro00016847, GSK-dHER2AS15, NCT00952692